NOD/ShiLtJGpt-Prkdc^em26Cd52Il2rg^em26Cd22/Gpt

NCG|Strain NO.T001475

Knockout (KO)

Product Type:
Quantity: - +
Sex:
Age:
Genotype:

BASIC INFORMATION

Strain Name:	NOD/ShiLtJGpt-Prkdc^em26Cd52Il2rg^em26Cd22/Gpt
Strain Number:	T001475
Official Symbol:	Prkdc,Il2rg
Strain Strategy:	T001475.NCG strain info.pdf
Official Full Name:	protein kinase DNA activated catalytic polypeptide,interleukin 2 receptor gamma chain
Also Known As:	AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460
NCBI Number:	19090 16186
MGI Number:	104779 96551
Research Areas:	Humanized model,Humanization of the immune system,Immunodeficiency
Strain Background:	[N000235] NOD/ShiLtJGpt
Modification Type:	Knockout (KO)
Inventory Status:	Live,Cryopreserved
Sale Status:	IF (Available for Distribution)
Health Status:	Specific pathogen free (SPF)
Health Report:	Please log in to view
Publications:	1. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment 2. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling 3. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML 4. Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer 5. Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment 6. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates 7. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3 8. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1 9. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling 10. Creatine promotes cancer metastasis through activation of Smad2/3 11. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells 12. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia 13. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors 14. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy 15. The Rational Development of CD5-targeting Biepitopic Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains 16. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression 17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors 18. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression 19. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness 20. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy 21. Dendrimer-Functionalized Superparamagnetic Nanobeacons for Real-Time Detection and Depletion of HSP90α mRNA and MR Imaging 22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study 23. OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling 24. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL 25. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer 26. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma 27. Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy 28. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance 29. Hook&Loop multivalent interactions based on disk-shaped nanoparticles strengthen active targeting 30. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy 31. BPA‐Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model 32. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-kappaB signaling in vivo 33. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1 34. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche 35. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma 36. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance 37. Impaired histone inheritance promotes tumor progression 38. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1 39. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/beta-catenin positive feedback loop 40. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer 41. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma 42. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment 43. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models 44. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma 45. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma 46. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin 47. WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia 48. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity 49. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells 50. The application of HER2 and CD47 CAR-macrophage in ovarian cancer 51. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy 52. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options 53. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma 54. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression 55. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer 56. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway 57. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity 58. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models 59. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT 60. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer 61. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51 62. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma 63. Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway 64. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application 65. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma 66. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma 67. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming 68. Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity 69. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects 70. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2alpha blockade by facilitating LDHA phosphorylation 71. Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting 72. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts 73. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)74. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma 75. Endoplasmic reticulum aminopeptidase 2 regulates CD4(+) T cells pyroptosis in rheumatoid arthritis 76. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9 77. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement 78. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma 79. RORalpha is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis 80. High-fat diet promotes prostate cancer metastasis via RPS27 81. CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma 82. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments 83. RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid 84. Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody 85. Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer 86. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial 87. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology 88. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy 89. GATA3 functions downstream of BRCA1 to promote DNA damage repair and suppress dedifferentiation in breast cancer 90. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/beta-catenin/PD-L1 axis 91. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia 92. PTPLAD1 Regulates PHB-Raf Interaction to Orchestrate Epithelial-Mesenchymal and Mitofusion-Fission Transitions in Colorectal Cancer 93. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion 94. Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer 95. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells 96. Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1 97. CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival 98. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes 99. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2 100. Expand available targets for CAR-T therapy to overcome tumor drug resistance based on the "Evolutionary Traps"101. NCX1/Ca(2+) promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFkappaB signaling pathway 102. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells 103. Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN 104. Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway 105. An herbal formula Shenlian decoction upregulates M1/M2 macrophage proportion in hepatocellular carcinoma by suppressing complement cascade 106. EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion 107. Liensinine diperchlorate and artemisitene synergistically attenuate breast cancer progression through suppressing PI3K-AKT signaling and their efficiency in breast cancer patient-derived organoids 108. Preclinical evaluation of cyclophosphamide and fludarabine combined with CD19 CAR-T in the treatment of B-cell hematologic malignancies in vivo 109. A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against ban 110. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis 111. A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy 112. Further evidence from DNAH12 supports favorable fertility outcomes of infertile males with dynein axonemal heavy chain gene family variants 113. N(6)-methyladenosine modification of circMARK2 enhances cytoplasmic export and stabilizes LIN28B, contributing to the progression of Wilms tumor 114. Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin 115. Pancreatic STAT5 activation promotes Kras(G12D)-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer 116. RSL3 enhances ROS-mediated cell apoptosis of myelodysplastic syndrome cells through MYB/Bcl-2 signaling pathway 117. ATP6V0A1-dependent cholesterol absorption in colorectal cancer cells triggers immunosuppressive signaling to inactivate memory CD8(+) T cells 118. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy 119. PIM1/NF-kappaB/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC 120. Tumor-intrinsic P2RY6 drives immunosuppression by enhancing PGE(2) production 121. Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy 122. COLEC10 inhibits the stemness of hepatocellular carcinoma by suppressing the activity of beta-catenin signaling 123. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma 124. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD(+) acute myeloid leukemia by inhibiting beta-catenin activity via the PP2A-GSK3beta axis 125. ALKBH5 governs human endoderm fate by regulating the DKK1/4-mediated Wnt/beta-catenin activation 126. Mito-LND and (E)-Akt inhibitor-IV: novel compounds inducing endoplasmic reticulum stress and ROS accumulation against hepatocellular carcinoma 127. PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells 128. Development of a Novel Peptide-Based PET Tracer [(68)Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma 129. Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance 130. Reshaping tumor microenvironment by regulating local cytokines expression with a portable smart blue-light controlled device 131. CBX2 enhances the progression and TMZ chemoresistance of glioma via EZH2-mediated epigenetic silencing of PTEN expression 132. PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability 133. A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia 134. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer 135. Single-cell RNA sequencing reveals transcriptomic landscape and potential targets for human testicular ageing.136. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells 137. Aligned fibrous scaffolds promote directional migration of breast cancer cells via caveolin-1/YAP-mediated mechanosensing 138. BTN3A1 expressed in cervical cancer cells promotes Vγ9Vδ2 T cells exhaustion through upregulating transcription factors NR4A2/3 downstream of TCR signaling 139. NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia 140. The 8‐oxoguanine DNA glycosylase‐synaptotagmin 7 pathway increases extracellular vesicle release and promotes tumour metastasis during oxidative stress 141. Human intermediate prostate cancer stem cells contribute to the initiation and development of prostate adenocarcinoma 142. Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets 143. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon 144. EphA2 specific chimeric antigen receptor engineered T cells for the treatment of prostate cancer 145. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models 146. YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer 147. ACSL6-activated IL-18R1–NF-κB promotes IL-18–mediated tumor immune evasion and tumor progression.148. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells